title: Efficacy of Liposomal Monensin on the Enhancement of the Antitumour Activity of Liposomal Ricin in Human Epidermoid Carcinoma (KB) Cells.
abstract: The monensin, known to enhance the cytotoxicity of ricin and ricin-based immunotoxins is a very hydrophobic molecule and this limits its administration in optimum doses under in vivo conditions. In order to realise its full potential, monensin was intercalated into various liposomal formulations and its ability to potentiate the cytotoxicity of ricin liposomes in human epidermoid carcinoma (KB) cells was studied. It was observed that ricin cytotoxicity enhancing ability of monensin liposome depends on the surface charge as well as density and chain length of distearoyl phosphatidylethanolamine-methoxy polyethylene glycol present on the surface of liposomal monensin. Maximum potentiation on the cytotoxicity of liposomal ricin was observed by monensin entrapped in neutral liposome (106.5 fold) followed by negatively charged (94.2 fold) and positively charged liposome (90 fold). Studies on the effect of variation of density and chain length of distearoyl phosphatidylethanolamine-methoxy polyethylene glycol showed that neutral monensin liposomes having 2.5 mol% distearoyl phosphatidylethanolamine-methoxy polyethylene glycol with chain length of 2000 exhibits maximum potentiation (117.6 fold) on the cytotoxicity of ricin liposomes when the cellular uptake of monensin liposome was maximum (42.0%) and the zeta potential value on the surface of liposomes was -0.645. The present study has clearly shown that liposomal monensin is very effective in enhancing the cytotoxicity of liposomal ricin in human cancer cells and liposome can be used as in vivo deliver vehicle for monensin to potentiate the cytotoxicity of liposomal ricin to eliminate cancer cells.
authors.affiliation: Department of Oncologic Sciences, Mitchel Cancer Institute, University of South Alabama, Mobile, Alabama, USA.
authors.forename: N
authors.initials: N
authors.lastname: Tyagi
authors.forename: S S
authors.initials: SS
authors.lastname: Rathore
authors.forename: P C
authors.initials: PC
authors.lastname: Ghosh
keywords: Human cancer cells; liposomal monensin; liposomal ricin; sterically stabilized liposomes; zeta potential
references.citation: Int J Pharm. 2002 Jun 20;240(1-2):95-102
references.pmid: 12062505
references.citation: Anal Biochem. 1980 May 1;104(1):10-4
references.pmid: 6892980
references.citation: J Liposome Res. 2005;15(3-4):199-213
references.pmid: 16393911
references.citation: Int J Pharm. 2008 Feb 28;350(1-2):79-94
references.pmid: 17913409
references.citation: J Liposome Res. 2003 May;13(2):157-72
references.pmid: 12855110
references.citation: FEBS Lett. 1994 Oct 10;353(1):71-4
references.pmid: 7926026
references.citation: Biochim Biophys Acta. 1992 Jun 12;1116(3):315-23
references.pmid: 1377030
references.citation: Biochim Biophys Acta. 1991 Jan 9;1061(1):56-64
references.pmid: 1995057
references.citation: Indian J Biochem Biophys. 1993 Dec;30(6):405-10
references.pmid: 8005625
references.citation: Biochim Biophys Acta. 1992 Sep 21;1110(1):37-44
references.pmid: 1390834
references.citation: Cancer Lett. 1994 Aug 29;84(1):15-21
references.pmid: 8076359
references.citation: J Biol Chem. 1987 Apr 25;262(12):5908-12
references.pmid: 3571242
references.citation: Trends Biotechnol. 1995 Dec;13(12):527-37
references.pmid: 8595139
references.citation: J Pharm Pharmacol. 2003 Jun;55(6):819-25
references.pmid: 12841943
references.citation: Drug Deliv. 2011 Aug;18(6):394-404
references.pmid: 21438723
references.citation: Int J Toxicol. 2006 Sep-Oct;25(5):349-59
references.pmid: 16940007
references.citation: Biochem Int. 1992 Oct;28(2):287-95
references.pmid: 1456950
references.citation: J Natl Cancer Inst. 1993 Feb 17;85(4):292-8
references.pmid: 8426373
references.citation: Essays Biochem. 1980;16:49-98
references.pmid: 7002545